Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Instem hails contract extension for SEND platform; demand growing significantly

The client, described as a top-five pre-clinical contract research organisation, has increased the size of the deal by US$400,000 to US$500,000
researcher filling a vial
SEND stands for Standard for the Exchange of Nonclinical Data and Instem’s innovative system allows a more efficient review of information, “offering improved data quality, accessibility and predictability”

Instem Plc (LON:INS), the technology provider to the drugs industry, has announced a significant contract extension from a company using its SEND platform.

The client, described as a top-five pre-clinical contract research organisation, has increased the size of the deal by US$400,000 to US$500,000.

READ: Instem's increasingly SaaSy profile should improve revenue visibility and enhance margins

SEND stands for Standard for the Exchange of Nonclinical Data and Instem’s innovative system allows a more efficient review of information, “offering improved data quality, accessibility and predictability”.

Industry traction appears to be growing with 25 orders from 17 different clients during the two-month period ended February 28, compared with six for the equivalent period last year. 

The company said it has also extended “several orders” with existing clients and it has a healthy prospect pipeline.

WATCH: Instem welcomes significant contract extension for SEND platform

To help meet demand, Instem has recruited 10 new consultants and information scientists in the UK, US and India.

"Over 50% of the world's marketed drugs have been through some part of the Instem platform at some stage of their development,” said Instem chief executive, Phil Reason.

“Our market leading SEND technology platform and comprehensive service offering position us well to both upsell SEND services to existing clients and cross-sell SEND services to new customers.

"We remain excited about the SEND market dynamics and are delighted with the strong start to the current year.

“Given our growing pipeline of new business opportunities and our refocused sales operations, we look forward to building on this momentum during the rest of the current year."

 

 

View full INS profile View Profile

Instem Plc Timeline

Related Articles

Young girl with laptop
May 17 2018
After mulling for almost a year whether to "draw stumps" and sell out, MMX decided a better course of action was to be the party doing the consolidating
1534442111_IoT.jpg
August 16 2018
In March, it formed a joint venture with New Hope Data Technology Co Ltd, which is affiliated to conglomerate New Hope Group
Financial chart
August 19 2018
The portfolio analytics platform operator has been shrewd in its acquisition policy and the purchase of Delta from UBS may just be the best acquisition yet

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use